Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Daratumumab-based Therapy for Multiple Myeloma
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial will test whether a new combination therapy of drugs will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service